Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR
AimThis study aims to assess the impact of continued ranibizumab treatment for neovascular age-related macular degeneration on patients from the MARINA and ANCHOR randomised clinical studies who lost ≥3 lines of best-corrected visual acuity (BCVA) at any time during the first year of treatment.Metho...
Gespeichert in:
| Veröffentlicht in: | British journal of ophthalmology 2011-12, Vol.95 (12), p.1713-1718 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1718 |
|---|---|
| container_issue | 12 |
| container_start_page | 1713 |
| container_title | British journal of ophthalmology |
| container_volume | 95 |
| creator | Wolf, Sebastian Holz, Frank G Korobelnik, Jean-François Lanzetta, Paolo Mitchell, Paul Prünte, Christian Schmidt-Erfurth, Ursula Weichselberger, Andreas Hashad, Yehia |
| description | AimThis study aims to assess the impact of continued ranibizumab treatment for neovascular age-related macular degeneration on patients from the MARINA and ANCHOR randomised clinical studies who lost ≥3 lines of best-corrected visual acuity (BCVA) at any time during the first year of treatment.MethodsBaseline characteristics, mean BCVA over time and ocular adverse events (AEs) were evaluated both for patients whose BCVA loss occurred at any post-baseline visit and for patients whose BCVA loss was acute. The visit when the ≥3-line BCVA loss was detected was defined as the new baseline.ResultsContinued monthly ranibizumab treatment led to an improvement in mean BCVA from the new baseline. On average, patients with acute BCVA loss gained 11.9 letters at 3 months after the new baseline, compared with 0.3 letters gained with sham. No strong signals were detected in patient demographics and baseline characteristics for prognostic markers of BCVA loss. Furthermore, there was no pattern in the AE profile of patients with acute BCVA loss to suggest that BCVA recovery could be attributed to spontaneously resolving AEs.ConclusionContinued ranibizumab treatment appears to be beneficial for patients with neovascular age-related macular degeneration who experience a ≥3-line BCVA loss during the first year of treatment. |
| doi_str_mv | 10.1136/bjophthalmol-2011-300471 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_905675897</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4012522041</sourcerecordid><originalsourceid>FETCH-LOGICAL-b454t-927dc1b52c5afb795a68e793d68acdaad1908ff5bfb53f69936dc914b100207a3</originalsourceid><addsrcrecordid>eNqNkd9u0zAUxiPExMrgFZAlhLgK2Ekc29xVFbBJpdWmwQU31klstylOXGxnsPfggXFJtyGuuLJ8zu_8-74sQwS_IaSs3zY7t9_GLdje2bzAhOQlxhUjj7IZqWqeQkw8zmYYY5YTUpPT7GkIu_QtasKeZKcFEZTQms2yX-sxtq7XARlnrfvRDRsUt17r3HaDRjdd6NyArAsBqdH_yXoNsddDRM6gQbsbCO1owSPY6NxrC1Er1MMUU3qjB-0hpi7vUBibjXfjHsEA9jYchnrXo0_zq4vVPAUVmq8W5-urZ9mJARv08-N7ln3-8P56cZ4v1x8vFvNl3lS0irkomGpJQ4uWgmmYoFBzzUSpag6tAlBEYG4MbUxDS1MLUdaqFaRqSBICMyjPstdT371330cdouy70GprId01Bilw0ohywRL58h9y50afrgiSMMZFRTnBieIT1fokmNdG7n3Xg7-VBMuDcfJv4-TBODkZl0pfHAeMTa_VfeGdUwl4dQSS3mCNh6HtwgNXMV4UWCQun7guRP3zPg_-m0xdGJWrLwv5lYrL8losJU98OfFNv_v_dX8DeALG-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1778945810</pqid></control><display><type>article</type><title>Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR</title><source>Open Access: PubMed Central</source><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Wolf, Sebastian ; Holz, Frank G ; Korobelnik, Jean-François ; Lanzetta, Paolo ; Mitchell, Paul ; Prünte, Christian ; Schmidt-Erfurth, Ursula ; Weichselberger, Andreas ; Hashad, Yehia</creator><creatorcontrib>Wolf, Sebastian ; Holz, Frank G ; Korobelnik, Jean-François ; Lanzetta, Paolo ; Mitchell, Paul ; Prünte, Christian ; Schmidt-Erfurth, Ursula ; Weichselberger, Andreas ; Hashad, Yehia</creatorcontrib><description>AimThis study aims to assess the impact of continued ranibizumab treatment for neovascular age-related macular degeneration on patients from the MARINA and ANCHOR randomised clinical studies who lost ≥3 lines of best-corrected visual acuity (BCVA) at any time during the first year of treatment.MethodsBaseline characteristics, mean BCVA over time and ocular adverse events (AEs) were evaluated both for patients whose BCVA loss occurred at any post-baseline visit and for patients whose BCVA loss was acute. The visit when the ≥3-line BCVA loss was detected was defined as the new baseline.ResultsContinued monthly ranibizumab treatment led to an improvement in mean BCVA from the new baseline. On average, patients with acute BCVA loss gained 11.9 letters at 3 months after the new baseline, compared with 0.3 letters gained with sham. No strong signals were detected in patient demographics and baseline characteristics for prognostic markers of BCVA loss. Furthermore, there was no pattern in the AE profile of patients with acute BCVA loss to suggest that BCVA recovery could be attributed to spontaneously resolving AEs.ConclusionContinued ranibizumab treatment appears to be beneficial for patients with neovascular age-related macular degeneration who experience a ≥3-line BCVA loss during the first year of treatment.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjophthalmol-2011-300471</identifier><identifier>PMID: 21951567</identifier><identifier>CODEN: BJOPAL</identifier><language>eng</language><publisher>BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd</publisher><subject>Aged ; Angiogenesis Inhibitors - therapeutic use ; angiogenesisretina ; Anti-VEGF ; Antibodies, Monoclonal, Humanized - therapeutic use ; Biological and medical sciences ; choroid ; Choroidal Neovascularization - drug therapy ; Choroidal Neovascularization - physiopathology ; clinical trial ; degeneration ; Double-Blind Method ; epidemiology ; Female ; Humans ; imaging ; maculaneovascularisation ; Macular degeneration ; Macular Degeneration - drug therapy ; Macular Degeneration - physiopathology ; Male ; Marinas ; Medical sciences ; Miscellaneous ; neovascular AMD ; neovascularisation ; Ophthalmology ; pathology ; Patients ; physiologypathology ; Prospective Studies ; public health ; Ranibizumab ; retina ; Retinopathies ; treatment lasers ; treatment medical ; treatment other ; Treatment Outcome ; treatment outcomes ; treatment surgery ; Vision disorders ; Visual Acuity</subject><ispartof>British journal of ophthalmology, 2011-12, Vol.95 (12), p.1713-1718</ispartof><rights>2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright: 2011 (c) 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b454t-927dc1b52c5afb795a68e793d68acdaad1908ff5bfb53f69936dc914b100207a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://bjo.bmj.com/content/95/12/1713.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://bjo.bmj.com/content/95/12/1713.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3194,23570,27923,27924,77371,77402</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24782209$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21951567$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wolf, Sebastian</creatorcontrib><creatorcontrib>Holz, Frank G</creatorcontrib><creatorcontrib>Korobelnik, Jean-François</creatorcontrib><creatorcontrib>Lanzetta, Paolo</creatorcontrib><creatorcontrib>Mitchell, Paul</creatorcontrib><creatorcontrib>Prünte, Christian</creatorcontrib><creatorcontrib>Schmidt-Erfurth, Ursula</creatorcontrib><creatorcontrib>Weichselberger, Andreas</creatorcontrib><creatorcontrib>Hashad, Yehia</creatorcontrib><title>Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><description>AimThis study aims to assess the impact of continued ranibizumab treatment for neovascular age-related macular degeneration on patients from the MARINA and ANCHOR randomised clinical studies who lost ≥3 lines of best-corrected visual acuity (BCVA) at any time during the first year of treatment.MethodsBaseline characteristics, mean BCVA over time and ocular adverse events (AEs) were evaluated both for patients whose BCVA loss occurred at any post-baseline visit and for patients whose BCVA loss was acute. The visit when the ≥3-line BCVA loss was detected was defined as the new baseline.ResultsContinued monthly ranibizumab treatment led to an improvement in mean BCVA from the new baseline. On average, patients with acute BCVA loss gained 11.9 letters at 3 months after the new baseline, compared with 0.3 letters gained with sham. No strong signals were detected in patient demographics and baseline characteristics for prognostic markers of BCVA loss. Furthermore, there was no pattern in the AE profile of patients with acute BCVA loss to suggest that BCVA recovery could be attributed to spontaneously resolving AEs.ConclusionContinued ranibizumab treatment appears to be beneficial for patients with neovascular age-related macular degeneration who experience a ≥3-line BCVA loss during the first year of treatment.</description><subject>Aged</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>angiogenesisretina</subject><subject>Anti-VEGF</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>choroid</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Choroidal Neovascularization - physiopathology</subject><subject>clinical trial</subject><subject>degeneration</subject><subject>Double-Blind Method</subject><subject>epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>imaging</subject><subject>maculaneovascularisation</subject><subject>Macular degeneration</subject><subject>Macular Degeneration - drug therapy</subject><subject>Macular Degeneration - physiopathology</subject><subject>Male</subject><subject>Marinas</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>neovascular AMD</subject><subject>neovascularisation</subject><subject>Ophthalmology</subject><subject>pathology</subject><subject>Patients</subject><subject>physiologypathology</subject><subject>Prospective Studies</subject><subject>public health</subject><subject>Ranibizumab</subject><subject>retina</subject><subject>Retinopathies</subject><subject>treatment lasers</subject><subject>treatment medical</subject><subject>treatment other</subject><subject>Treatment Outcome</subject><subject>treatment outcomes</subject><subject>treatment surgery</subject><subject>Vision disorders</subject><subject>Visual Acuity</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkd9u0zAUxiPExMrgFZAlhLgK2Ekc29xVFbBJpdWmwQU31klstylOXGxnsPfggXFJtyGuuLJ8zu_8-74sQwS_IaSs3zY7t9_GLdje2bzAhOQlxhUjj7IZqWqeQkw8zmYYY5YTUpPT7GkIu_QtasKeZKcFEZTQms2yX-sxtq7XARlnrfvRDRsUt17r3HaDRjdd6NyArAsBqdH_yXoNsddDRM6gQbsbCO1owSPY6NxrC1Er1MMUU3qjB-0hpi7vUBibjXfjHsEA9jYchnrXo0_zq4vVPAUVmq8W5-urZ9mJARv08-N7ln3-8P56cZ4v1x8vFvNl3lS0irkomGpJQ4uWgmmYoFBzzUSpag6tAlBEYG4MbUxDS1MLUdaqFaRqSBICMyjPstdT371330cdouy70GprId01Bilw0ohywRL58h9y50afrgiSMMZFRTnBieIT1fokmNdG7n3Xg7-VBMuDcfJv4-TBODkZl0pfHAeMTa_VfeGdUwl4dQSS3mCNh6HtwgNXMV4UWCQun7guRP3zPg_-m0xdGJWrLwv5lYrL8losJU98OfFNv_v_dX8DeALG-g</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Wolf, Sebastian</creator><creator>Holz, Frank G</creator><creator>Korobelnik, Jean-François</creator><creator>Lanzetta, Paolo</creator><creator>Mitchell, Paul</creator><creator>Prünte, Christian</creator><creator>Schmidt-Erfurth, Ursula</creator><creator>Weichselberger, Andreas</creator><creator>Hashad, Yehia</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR</title><author>Wolf, Sebastian ; Holz, Frank G ; Korobelnik, Jean-François ; Lanzetta, Paolo ; Mitchell, Paul ; Prünte, Christian ; Schmidt-Erfurth, Ursula ; Weichselberger, Andreas ; Hashad, Yehia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b454t-927dc1b52c5afb795a68e793d68acdaad1908ff5bfb53f69936dc914b100207a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>angiogenesisretina</topic><topic>Anti-VEGF</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>choroid</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Choroidal Neovascularization - physiopathology</topic><topic>clinical trial</topic><topic>degeneration</topic><topic>Double-Blind Method</topic><topic>epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>imaging</topic><topic>maculaneovascularisation</topic><topic>Macular degeneration</topic><topic>Macular Degeneration - drug therapy</topic><topic>Macular Degeneration - physiopathology</topic><topic>Male</topic><topic>Marinas</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>neovascular AMD</topic><topic>neovascularisation</topic><topic>Ophthalmology</topic><topic>pathology</topic><topic>Patients</topic><topic>physiologypathology</topic><topic>Prospective Studies</topic><topic>public health</topic><topic>Ranibizumab</topic><topic>retina</topic><topic>Retinopathies</topic><topic>treatment lasers</topic><topic>treatment medical</topic><topic>treatment other</topic><topic>Treatment Outcome</topic><topic>treatment outcomes</topic><topic>treatment surgery</topic><topic>Vision disorders</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wolf, Sebastian</creatorcontrib><creatorcontrib>Holz, Frank G</creatorcontrib><creatorcontrib>Korobelnik, Jean-François</creatorcontrib><creatorcontrib>Lanzetta, Paolo</creatorcontrib><creatorcontrib>Mitchell, Paul</creatorcontrib><creatorcontrib>Prünte, Christian</creatorcontrib><creatorcontrib>Schmidt-Erfurth, Ursula</creatorcontrib><creatorcontrib>Weichselberger, Andreas</creatorcontrib><creatorcontrib>Hashad, Yehia</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wolf, Sebastian</au><au>Holz, Frank G</au><au>Korobelnik, Jean-François</au><au>Lanzetta, Paolo</au><au>Mitchell, Paul</au><au>Prünte, Christian</au><au>Schmidt-Erfurth, Ursula</au><au>Weichselberger, Andreas</au><au>Hashad, Yehia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR</atitle><jtitle>British journal of ophthalmology</jtitle><addtitle>Br J Ophthalmol</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>95</volume><issue>12</issue><spage>1713</spage><epage>1718</epage><pages>1713-1718</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><coden>BJOPAL</coden><abstract>AimThis study aims to assess the impact of continued ranibizumab treatment for neovascular age-related macular degeneration on patients from the MARINA and ANCHOR randomised clinical studies who lost ≥3 lines of best-corrected visual acuity (BCVA) at any time during the first year of treatment.MethodsBaseline characteristics, mean BCVA over time and ocular adverse events (AEs) were evaluated both for patients whose BCVA loss occurred at any post-baseline visit and for patients whose BCVA loss was acute. The visit when the ≥3-line BCVA loss was detected was defined as the new baseline.ResultsContinued monthly ranibizumab treatment led to an improvement in mean BCVA from the new baseline. On average, patients with acute BCVA loss gained 11.9 letters at 3 months after the new baseline, compared with 0.3 letters gained with sham. No strong signals were detected in patient demographics and baseline characteristics for prognostic markers of BCVA loss. Furthermore, there was no pattern in the AE profile of patients with acute BCVA loss to suggest that BCVA recovery could be attributed to spontaneously resolving AEs.ConclusionContinued ranibizumab treatment appears to be beneficial for patients with neovascular age-related macular degeneration who experience a ≥3-line BCVA loss during the first year of treatment.</abstract><cop>BMA House, Tavistock Square, London, WC1H 9JR</cop><pub>BMJ Publishing Group Ltd</pub><pmid>21951567</pmid><doi>10.1136/bjophthalmol-2011-300471</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1161 |
| ispartof | British journal of ophthalmology, 2011-12, Vol.95 (12), p.1713-1718 |
| issn | 0007-1161 1468-2079 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_905675897 |
| source | Open Access: PubMed Central; MEDLINE; BMJ Journals - NESLi2 |
| subjects | Aged Angiogenesis Inhibitors - therapeutic use angiogenesisretina Anti-VEGF Antibodies, Monoclonal, Humanized - therapeutic use Biological and medical sciences choroid Choroidal Neovascularization - drug therapy Choroidal Neovascularization - physiopathology clinical trial degeneration Double-Blind Method epidemiology Female Humans imaging maculaneovascularisation Macular degeneration Macular Degeneration - drug therapy Macular Degeneration - physiopathology Male Marinas Medical sciences Miscellaneous neovascular AMD neovascularisation Ophthalmology pathology Patients physiologypathology Prospective Studies public health Ranibizumab retina Retinopathies treatment lasers treatment medical treatment other Treatment Outcome treatment outcomes treatment surgery Vision disorders Visual Acuity |
| title | Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T19%3A17%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20following%20three-line%20vision%20loss%20during%20treatment%20of%20neovascular%20age-related%20macular%20degeneration:%20subgroup%20analyses%20from%20MARINA%20and%20ANCHOR&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Wolf,%20Sebastian&rft.date=2011-12-01&rft.volume=95&rft.issue=12&rft.spage=1713&rft.epage=1718&rft.pages=1713-1718&rft.issn=0007-1161&rft.eissn=1468-2079&rft.coden=BJOPAL&rft_id=info:doi/10.1136/bjophthalmol-2011-300471&rft_dat=%3Cproquest_cross%3E4012522041%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1778945810&rft_id=info:pmid/21951567&rfr_iscdi=true |